Analyzing R&D Budgets: Opthea Limited vs Dynavax Technologies Corporation

R&D Spending: Opthea's Surge vs Dynavax's Steady Path

__timestampDynavax Technologies CorporationOpthea Limited
Wednesday, January 1, 2014845800003401685
Thursday, January 1, 2015869430004284228
Friday, January 1, 2016844930003581295
Sunday, January 1, 2017649880004838300
Monday, January 1, 20187495100024891534
Tuesday, January 1, 20196233100031347891
Wednesday, January 1, 20202860700017480747
Friday, January 1, 20213222800034710152
Saturday, January 1, 202246600000108459978
Sunday, January 1, 202354886000181563523
Monday, January 1, 2024176326321
Loading chart...

Data in motion

A Tale of Two Innovators: Opthea Limited vs Dynavax Technologies Corporation

In the ever-evolving landscape of biotechnology, research and development (R&D) budgets are a key indicator of a company's commitment to innovation. Over the past decade, Opthea Limited and Dynavax Technologies Corporation have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Dynavax's R&D expenses peaked in 2015, with a notable 87 million USD, before experiencing a gradual decline. In contrast, Opthea's R&D spending surged dramatically, increasing by over 5000% from 2014 to 2023, reaching a high of approximately 182 million USD. This stark difference highlights Opthea's aggressive push towards innovation, particularly in recent years. The data for 2024 is incomplete, but the trend suggests Opthea's continued focus on R&D. As these companies forge ahead, their R&D strategies will likely play a pivotal role in shaping their future success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025